Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy. Methods: The clinical efficacy was assessed based on SELECT-CH...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2021-07-01
|
Series: | Global & Regional Health Technology Assessment |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2267 |